A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Phase 2 Completed
47 enrolled 8 charts
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Phase 1/2 Completed
55 enrolled 17 charts
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Phase 3 Completed
1,334 enrolled 23 charts
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Phase 2 Completed
82 enrolled 20 charts
KEYNOTE145
Phase 1/2 Completed
161 enrolled 29 charts
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Phase 2 Completed
34 enrolled 14 charts
BV-ICE
Phase 1/2 Completed
45 enrolled 14 charts
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
MK-3475-B68
Phase 2 Completed
66 enrolled 16 charts
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Phase 1/2 Completed
320 enrolled 35 charts
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 2 Completed
66 enrolled 14 charts
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/2 Completed
3 enrolled 10 charts
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
Phase 1/2 Completed
50 enrolled 10 charts
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 2 Completed
78 enrolled 16 charts
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Phase 2 Completed
28 enrolled 10 charts
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 14 charts
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase 2 Completed
61 enrolled 10 charts
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase 1/2 Completed
64 enrolled 13 charts
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 2 Completed
28 enrolled 11 charts
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
20 enrolled 12 charts
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Phase 2 Completed
211 enrolled 22 charts
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Phase 1/2 Completed
36 enrolled 26 charts
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 2 Completed
117 enrolled 40 charts
Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer
Phase 2 Completed
62 enrolled 7 charts
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Phase 2 Completed
75 enrolled 10 charts
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
Phase 2 Completed
37 enrolled 6 charts
CheckMate 205
Phase 2 Completed
294 enrolled 32 charts
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Phase 2 Completed
50 enrolled 23 charts
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
Completed
10 enrolled 3 charts
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
Phase 2 Completed
76 enrolled 10 charts
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Phase 2 Completed
23 enrolled 10 charts
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Phase 1/2 Completed
140 enrolled 23 charts
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Phase 2 Completed
6 enrolled 10 charts
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Phase 2 Completed
25 enrolled 10 charts
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Phase 2 Completed
81 enrolled 81 charts
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Phase 2 Completed
127 enrolled 20 charts
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
Phase 2 Completed
22 enrolled 15 charts
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Phase 3 Completed
854 enrolled 9 charts
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Phase 2 Completed
201 enrolled 12 charts
An Open Label Dose Escalation Study Of E7080
Phase 1 Completed
82 enrolled 34 charts
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Phase 2 Completed
25 enrolled 10 charts
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase 1/2 Completed
58 enrolled 18 charts
Autologous Transplant in HIV Patients (BMT CTN 0803)
Phase 2 Completed
43 enrolled 21 charts
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
Phase 2 Completed
86 enrolled 11 charts
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Phase 1/2 Completed
93 enrolled 13 charts
Therapy for Pediatric Hodgkin Lymphoma
Phase 2 Completed
296 enrolled 28 charts
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Phase 2 Completed
50 enrolled 13 charts